Sunday November 19th 2017

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec and Sangamo BioSciences, Inc. announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin.

From: 

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Leave a Comment

More from category

Gut bacteria at young age can contribute to MS disease onset and progression, study suggests
Gut bacteria at young age can contribute to MS disease onset and progression, study suggests

Researchers at Rutgers Robert Wood Johnson Medical School published a study suggesting that gut bacteria at young age [Read More]

Age and gut bacteria contribute to MS disease progression, according to Rutgers
Age and gut bacteria contribute to MS disease progression, according to Rutgers

(Rutgers University) Gut bacteria at a young age can contribute to multiple sclerosis disease onset and progression. [Read More]

Virtual reality training may be effective alternative to standard therapy after stroke
Virtual reality training may be effective alternative to standard therapy after stroke

Using virtual reality therapy to improve arm and hand movement after a stroke is equally as effective as regular [Read More]

Social care failing people with disabilities, says leading charity
Social care failing people with disabilities, says leading charity

Young people with MS forced to live in care homes for older people Related items fromOnMedica Social care set to eat up [Read More]

World’s Largest MS Research Conference Features Advances in Progressive MS, Myelin Repair, Lifestyle
World’s Largest MS Research Conference Features Advances in Progressive MS, Myelin Repair, Lifestyle

/About-the-Society/News/World’s-Largest-MS-Research-Conference-Features-Ad [Read More]